Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | LDHA | P00338 | 1/20 | 0.56 |
| ▸ | KIF11 | P52732 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | PCNA | P12004 | 1/20 | 0.46 |
| ▸ | LIG1 | P18858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16767542 | 1.00 | SLC6A4 (0.66) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL334385 | 1.00 | SLC6A4 (0.66) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL12379300 | 0.94 | SLC6A4 (0.59) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| Hydrochloric Acid SCHEMBL2292948 | 0.93 | SLC6A4 (0.58) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL656814 | 0.90 | SLC6A4 (0.73) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| Hydrochloric Acid SCHEMBL6540026 | 0.86 | PKM (0.56) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| Hydrochloric Acid SCHEMBL6540034 | 0.86 | PKM (0.56) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL1586263 | 0.84 | SLC6A4 (0.66) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL13354941 | 0.84 | SLC6A4 (0.66) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL1586261 | 0.84 | SLC6A4 (0.66) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4516778-A1 | COMPOUND SERVING AS DDR1 KINASE INHIBITOR, AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2025-03-05 | — | — | EP | disclosed |
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | C4 THERAPEUTICS, INC. | 2024-10-17 | — | — | US | disclosed |
| EP-3515896-B1 | CHIRAL CYCLEN COMPOUNDS AND THEIR USES | UNIV HONG KONG POLYTECHNIC (CN) | 2024-08-21 | — | — | EP | disclosed |
| EP-4367113-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | Biogen MA Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-117940414-A | Compounds for targeting IRAK4 protein degradation | 渤健马萨诸塞州股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2023210599-A1 | COMPOUND SERVING AS DDR1 KINASE INHIBITOR, AND MEDICINE | 日本新薬株式会社 | 2023-11-02 | — | — | WO | disclosed |
| WO-2023283610-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| US-11357873-B2 | Chiral cyclen compounds and their uses | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20210283278-A1 | CHIRAL CYCLEN COMPOUNDS AND THEIR USES | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2021-09-16 | — | — | US | disclosed |
| EP-2941427-B1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | PF MEDICAMENT (FR) | 2016-11-09 | — | — | EP | disclosed |
| US-6489331-B1 | A CONDENSED PURINE DERIVATIVE AS AN ACTIVE INGREDIENT AS AN ENHANCER OF INSULIN SECRETION AND A MEDICAMENT FOR THE TREATMENT OF DIABETES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| EP-1230218-A1 | POSITIVE MODULATORS OF NICOTINIC RECEPTOR AGONISTS | AstraZeneca AB (SE) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001032622-A1 | POSITIVE MODULATORS OF NICOTINIC RECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2001-05-10 | — | — | WO | disclosed |
| EP-1092435-A1 | REMEDIES FOR DIABETES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-04-18 | — | — | EP | disclosed |
| WO-2001009127-A1 | BENZOXAZINE DERIVATIVES AND THEIR THERAPEUTIC USE | AVENTIS PHARMA S.A. (FR) | 2001-02-08 | — | — | WO | disclosed |
| EP-0391107-A1 | Benzazepine derivatives | E.R. SQUIBB & SONS, INC. (US) | 1990-10-10 | — | — | EP | disclosed |
| US-4952692-A | Benzazepine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1990-08-28 | — | — | US | disclosed |
| US-4097608-A | Anti-ulcerous tyrosine derivatives | DAIICHI SEIYAKU CO., LTD. (JA) | 1978-06-27 | — | — | US | disclosed |
| US-4057629-A | ANTIULCER | DAIICHI SEIYAKU CO., LTD. (JA) | 1977-11-08 | — | — | US | disclosed |
| US-4025644-A | ANTIULCER | DAIICHI SEIYAKU CO., LTD. (JA) | 1977-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357873-B2 | Chiral cyclen compounds and their uses | DCTN3, DCTN1, CDK3 | SLC6A4 981/4885CYP1A2 2754/4885CYP2D6 3277/4885 |
| US-20210283278-A1 | CHIRAL CYCLEN COMPOUNDS AND THEIR USES | DCTN3, DCTN1, CDK3 | SLC6A4 981/4885CYP1A2 2754/4885CYP2D6 3277/4885 |
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | IRAK4, IRAK2, IRAK1 | SLC6A4 3168/4885CYP1A2 4773/4885CYP2D6 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.